Unique ID issued by UMIN | UMIN000012841 |
---|---|
Receipt number | R000015000 |
Scientific Title | The safety and usability assessment of sunscreen agents (cosmetics) for light-sensitive patients |
Date of disclosure of the study information | 2014/03/01 |
Last modified on | 2016/07/13 09:55:36 |
The safety and usability assessment of sunscreen agents (cosmetics) for light-sensitive patients
The safety and usability assessment of sunscreen agents
The safety and usability assessment of sunscreen agents (cosmetics) for light-sensitive patients
The safety and usability assessment of sunscreen agents
Japan |
Light-sensitive patients including such as xeroderma pigmentosum, chronic actinic dermatitis, photosensitivity dermatitis, drug-induced photosensitivity
Dermatology |
Others
NO
Veridation of the safety(10% or less rate of adverse effect) and usability in light-sensitive patients by applying sunscreen agents to sun-exposure area of the light-sensitive patients for 4 weeks
Safety,Efficacy
the safety(10% or less rate of adverse effect)
the usability(the changes of skin findings and cytokines in the stratum corneum)
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Prevention
Other |
Applying sunscreen agents to sun-exposure area of light-sensitive patients for 4 weeks
Not applicable |
Not applicable |
Male and Female
1.Patients diagnosed with photosensitivity, who is determined that the use of this reserch article is useful therapeutically
2.Regardless of age or sex
3.Patients (whose legal representative in the case of minors) are in agreement
In addition, we define photosensitivity as follows in this study.
1.photosensitivity disease including such as xeroderma pigmentosum, chronic actinic dermatitis, photosensitivity dermatitis,drug-induced photosensitivity
2.the diseases exacerbated by sun exposure including such as systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, dermatomyositis, rosacea-like dermatitis, Sjogren's syndrome
3.the diseases which is desirable to avoid sun exposure therapeutically for in improving disease, including atopic dermatitis, pigment spots (such as after laser treatment).
1.Those who have experience with the use of sunscreen agents, resulted in a skin severe symptoms in the past.
2.Those who have skin eruption on the application area of this research article.
3.The case that the interference of this reserch article and other topical product
is expected.
4.Pregnant or nursing women
5.Those who can not (in principle) be examined after 4 weeks
6.Those who are deemed inappropriate to participate in this study by doctor.
20
1st name | |
Middle name | |
Last name | Yoshiki Miyachi |
Kyoto University Hospital
Department of Dermatology
54 Shogoinkawahara-cho, Sakyo-ku,Kyoto, 6068507, Japan
075-751-3111
hifuka@kuhp.kyoto-u.ac.jp
1st name | |
Middle name | |
Last name | Akihiro Fujisawa |
Kyoto University Hospital
Department of Dermatology
54 Shogoinkawahara-cho, Sakyo-ku,Kyoto, 6068507, Japan
075-751-3111
fujiaki@kuhp.kyoto-u.ac.jp
Department of Dermatology, Graduate School of Medicine, Kyoto University
TOKIWA Pharmaceutical Co.,Ltd.
Profit organization
NO
2014 | Year | 03 | Month | 01 | Day |
Unpublished
Completed
2014 | Year | 01 | Month | 12 | Day |
2014 | Year | 04 | Month | 01 | Day |
2014 | Year | 01 | Month | 13 | Day |
2016 | Year | 07 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015000